Compare DFH & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | AAPG |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2020 | N/A |
| Metric | DFH | AAPG |
|---|---|---|
| Price | $16.62 | $18.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $26.00 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 631.0K | 16.4K |
| Earning Date | 05-12-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $4,322,848,000.00 | N/A |
| Revenue This Year | $0.81 | $290.34 |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $152.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.20 | $16.36 |
| 52 Week High | $31.10 | $48.45 |
| Indicator | DFH | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 52.57 |
| Support Level | $13.49 | $16.92 |
| Resistance Level | $20.26 | $25.23 |
| Average True Range (ATR) | 1.02 | 0.48 |
| MACD | 0.16 | 0.31 |
| Stochastic Oscillator | 68.85 | 100.00 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.